Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics

Virulence arresting drugs (VAD) are an expanding class of antimicrobial treatment that act to “disarm” rather than kill bacteria. Despite an increasing number of VAD being registered for clinical use, uptake is hampered by the lack of methods that can identify patients who are most likely to benefit...

Full description

Bibliographic Details
Main Authors: Vitali Sintchenko, Verlaine Timms, Eby Sim, Rebecca Rockett, Nathan Bachmann, Matthew O'Sullivan, Ben Marais
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.641260/full
id doaj-1894861c9fdb460ba099e12a086565e8
record_format Article
spelling doaj-1894861c9fdb460ba099e12a086565e82021-04-13T04:27:52ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-04-01810.3389/fmed.2021.641260641260Microbial Genomics as a Catalyst for Targeted Antivirulence TherapeuticsVitali Sintchenko0Vitali Sintchenko1Vitali Sintchenko2Verlaine Timms3Eby Sim4Rebecca Rockett5Rebecca Rockett6Nathan Bachmann7Matthew O'Sullivan8Matthew O'Sullivan9Matthew O'Sullivan10Ben Marais11Ben Marais12Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, NSW, AustraliaCentre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Westmead, NSW, AustraliaCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology—Institute of Clinical Pathology and Medical Research, Westmead, NSW, AustraliaCentre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Westmead, NSW, AustraliaCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology—Institute of Clinical Pathology and Medical Research, Westmead, NSW, AustraliaMarie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, NSW, AustraliaCentre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Westmead, NSW, AustraliaCentre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Westmead, NSW, AustraliaMarie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, NSW, AustraliaCentre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Westmead, NSW, AustraliaCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology—Institute of Clinical Pathology and Medical Research, Westmead, NSW, AustraliaMarie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, NSW, AustraliaChildren's Hospital at Westmead, Westmead, NSW, AustraliaVirulence arresting drugs (VAD) are an expanding class of antimicrobial treatment that act to “disarm” rather than kill bacteria. Despite an increasing number of VAD being registered for clinical use, uptake is hampered by the lack of methods that can identify patients who are most likely to benefit from these new agents. The application of pathogen genomics can facilitate the rational utilization of advanced therapeutics for infectious diseases. The development of genomic assessment of VAD targets is essential to support the early stages of VAD diffusion into infectious disease management. Genomic identification and characterization of VAD targets in clinical isolates can augment antimicrobial stewardship and pharmacovigilance. Personalized genomics guided use of VAD will provide crucial policy guidance to regulating agencies, assist hospitals to optimize the use of these expensive medicines and create market opportunities for biotech companies and diagnostic laboratories.https://www.frontiersin.org/articles/10.3389/fmed.2021.641260/fullvirulencegenome sequence analysisantibacterial treatmentsurveillanceantimicrobial stewardship
collection DOAJ
language English
format Article
sources DOAJ
author Vitali Sintchenko
Vitali Sintchenko
Vitali Sintchenko
Verlaine Timms
Eby Sim
Rebecca Rockett
Rebecca Rockett
Nathan Bachmann
Matthew O'Sullivan
Matthew O'Sullivan
Matthew O'Sullivan
Ben Marais
Ben Marais
spellingShingle Vitali Sintchenko
Vitali Sintchenko
Vitali Sintchenko
Verlaine Timms
Eby Sim
Rebecca Rockett
Rebecca Rockett
Nathan Bachmann
Matthew O'Sullivan
Matthew O'Sullivan
Matthew O'Sullivan
Ben Marais
Ben Marais
Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics
Frontiers in Medicine
virulence
genome sequence analysis
antibacterial treatment
surveillance
antimicrobial stewardship
author_facet Vitali Sintchenko
Vitali Sintchenko
Vitali Sintchenko
Verlaine Timms
Eby Sim
Rebecca Rockett
Rebecca Rockett
Nathan Bachmann
Matthew O'Sullivan
Matthew O'Sullivan
Matthew O'Sullivan
Ben Marais
Ben Marais
author_sort Vitali Sintchenko
title Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics
title_short Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics
title_full Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics
title_fullStr Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics
title_full_unstemmed Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics
title_sort microbial genomics as a catalyst for targeted antivirulence therapeutics
publisher Frontiers Media S.A.
series Frontiers in Medicine
issn 2296-858X
publishDate 2021-04-01
description Virulence arresting drugs (VAD) are an expanding class of antimicrobial treatment that act to “disarm” rather than kill bacteria. Despite an increasing number of VAD being registered for clinical use, uptake is hampered by the lack of methods that can identify patients who are most likely to benefit from these new agents. The application of pathogen genomics can facilitate the rational utilization of advanced therapeutics for infectious diseases. The development of genomic assessment of VAD targets is essential to support the early stages of VAD diffusion into infectious disease management. Genomic identification and characterization of VAD targets in clinical isolates can augment antimicrobial stewardship and pharmacovigilance. Personalized genomics guided use of VAD will provide crucial policy guidance to regulating agencies, assist hospitals to optimize the use of these expensive medicines and create market opportunities for biotech companies and diagnostic laboratories.
topic virulence
genome sequence analysis
antibacterial treatment
surveillance
antimicrobial stewardship
url https://www.frontiersin.org/articles/10.3389/fmed.2021.641260/full
work_keys_str_mv AT vitalisintchenko microbialgenomicsasacatalystfortargetedantivirulencetherapeutics
AT vitalisintchenko microbialgenomicsasacatalystfortargetedantivirulencetherapeutics
AT vitalisintchenko microbialgenomicsasacatalystfortargetedantivirulencetherapeutics
AT verlainetimms microbialgenomicsasacatalystfortargetedantivirulencetherapeutics
AT ebysim microbialgenomicsasacatalystfortargetedantivirulencetherapeutics
AT rebeccarockett microbialgenomicsasacatalystfortargetedantivirulencetherapeutics
AT rebeccarockett microbialgenomicsasacatalystfortargetedantivirulencetherapeutics
AT nathanbachmann microbialgenomicsasacatalystfortargetedantivirulencetherapeutics
AT matthewosullivan microbialgenomicsasacatalystfortargetedantivirulencetherapeutics
AT matthewosullivan microbialgenomicsasacatalystfortargetedantivirulencetherapeutics
AT matthewosullivan microbialgenomicsasacatalystfortargetedantivirulencetherapeutics
AT benmarais microbialgenomicsasacatalystfortargetedantivirulencetherapeutics
AT benmarais microbialgenomicsasacatalystfortargetedantivirulencetherapeutics
_version_ 1721529338048806912